Second Generation Antipsychotics in Asperger’s Disorder and High Functioning Autism: A Systematic Review of the Literature and Effectiveness of Meta-Analysis.
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Second generation antipsychotics (SGA) have gained increased evidence for the treatment of irritability and aggression in children and adolescents with lower functioning autistic disorder. Individuals with Asperger's Disorder (AD) and High Functioning Autism (HFA) experience significant emotional and behavioral problems and psychiatric comorbidity. There is a need to review the published literature on SGA treatment efficacy in the AD and HFA populations to provide more effective treatment choices for these subgroups. METHODS: We conducted a systematic review and meta-analysis of the recent English literature on SGA use in children and adolescents (ages 0-24 years) with AD and HFA using the Medline/PubMed and PsychINFO computerized databases. Key search words were 'Asperger', 'high functioning autism', 'autism spectrum disorders (ASD)', and 'pervasive developmental disorder (PDD)' in combination with 'second generation antipsychotics', 'aripiprazole; 'olanzapine', 'quetiapine', 'risperidone', or 'ziprasidone'. RESULTS: Our search yielded 214 citations, however only open-label or randomized-controlled trials (RCT) with ≥25% of their subjects having an IQ≥71 were included in our review. Eleven original studies met our inclusion parameters for review; eight studies for the meta-analysis. These studies, although limited in methodological rigor, and the meta-analytic results suggest that SGAs provide improvement in behavioral symptoms associated with AD and HFA. The majority of the studies reported weight gain as a potentially concerning adverse effect. CONCLUSION: There is a lack of robustly conducted trials on the use of SGAs in the management of AD and HFA. More research in pharmacological and psychosocial treatments is warranted. Clinicians are cautioned to approach pharmacological treatment prudently balancing benefit with potential cardiometabolic risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Epidemiology of Pervasive Developmental Disorders
Fombonne, E. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e31819e7203 · Cited by 1,971 · cited 1×
“6-6/10,000 [2, 3].”
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 2×
“Antipsychotic-related weight gain and metabolic adverse effects have became major issues in evaluating the risk-tobenefit ratio of using SGAs, in particular for children and youth who appear to be more susceptible to weight gain and metabolic adverse events [59,60].”
BackgroundAripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder
Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D., Carson, W. H., & Findling, R. L. (2009) · Pediatrics · doi:10.1542/peds.2008-3782 · Cited by 613 · cited 4×
“RCTs with aripiprazole [13-15] were not included as they studied the effect of aripiprazole in autistic disorder subjects excluding AD and PDD NOS subjects.”
BackgroundMethodInfluentialAman, M. G., Mcdougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., Stigler, K. A., Bearss, K., Butter, E., Swiezy, N. B., et al. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181bfd669 · Cited by 371 · cited 5×
“Despite casting a wider net, the collected studies were mostly of ‘Low’ quality evidence with only 2 studies based on the same study population [37, 38] considered to be of ‘Moderate’ quality.”
BackgroundMethodResultInfluentialSterling, L., Dawson, G., Estes, A., & Greenson, J. (2008) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-007-0477-y · Cited by 263
Risperidone in Children With Autism: Randomized, Placebo-Controlled, Double-Blind Study
Nagaraj, R., Singhi, P., & Malhi, P. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210060801 · Cited by 214
Munesue, T., Ono, Y., Mutoh, K., Shimoda, K., Nakatani, H., & Kikuchi, M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.02.015 · Cited by 120
Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Aman, M. G. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0121 · Cited by 82 · cited 2×
“RCTs with aripiprazole [13-15] were not included as they studied the effect of aripiprazole in autistic disorder subjects excluding AD and PDD NOS subjects.”
BackgroundMethodCognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Aman, M. G., Hollway, J. A., McDougle, C. J., Scahill, L., Tierney, E., McCracken, J. T., Arnold, L. E., Vitiello, B., Ritz, L., Gavaletz, A., et al. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0133 · Cited by 80 · cited 1×
“[57] published on the cognitive effects of risperidone treatment (0.”
Background
Cited by
Guastella, A. J., & Hickie, I. B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.06.028 · Cited by 223
Mast cells, brain inflammation and autism
Theoharides, T. C., Stewart, J. M., Panagiotidou, S., & Melamed, I. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.086 · Cited by 138
Rodrigues, R., Lai, M., Beswick, A., Gorman, D. A., Anagnostou, E., Szatmari, P., Anderson, K. K., & Ameis, S. H. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13305 · Cited by 98
Coleman, D. M., Adams, J. B., Anderson, A. L., & Frye, R. E. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0121 · Cited by 56
Metadata
- Authors
- Sochocky, N., & Milin, R.
- Venue
- Current Clinical Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-08-31
- Volume
- 8
- Issue
- 4
- Pages
- 370-379
- ISSN
- 1574-8847 (ISSN-L)
- OpenAlex
- W2312870890
- Cited by
- 25
- References
- 10
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second Generation Antipsychotics in Asperger’s Disorder and High Functioning Autism: A Systematic Review of the Literature and Effectiveness of Meta-Analysis. https://app.cochat.ai/papers/10.2174/15748847113086660073
- The paper
- Sochocky, N., & Milin, R. (2013). Second Generation Antipsychotics in Asperger’s Disorder and High Functioning Autism: A Systematic Review of the Literature and Effectiveness of Meta-Analysis. Current Clinical Pharmacology. https://doi.org/10.2174/15748847113086660073
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.